Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E6FS
|
|||
| Drug Name |
Rivaroxaban
|
|||
| Synonyms |
Xarelto; BAY 59-7939; UNII-9NDF7JZ4M3; BAY59-7939
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H18ClN3O5S
|
|||
| Canonical SMILES |
C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
|
|||
| InChI |
1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
|
|||
| InChIKey |
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
|
|||
| CAS Number |
CAS 366789-02-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:68579
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.